glp-1 treatment for newly diagnosed diabetes guidelines Where GLP-1RAs fit into current T2DM guidelines. Reproduced with GLP-1 agonists and changes in

It functions as a GLP-1 receptor agonist, targeting brain areas responsible for appetite control , thereby helping to decrease hunger and reduce calorie intake

Not as easy as a weekly injection, but it works

The goal should be safer progress, better habits, and a plan that patients can maintain

Retatrutide, a triple agonist, adds glucagon receptor activation to the GLP-1 and GIP activation

What Recent Research and Regulatory Updates Show A 2024 Danish study found that adults with type 2 diabetes who used semaglutide once a week were more than twice as likely to develop NAION within five years compared with non-users (HR 2.19), with a median onset of 22 months after starting the medication